[HTML][HTML] Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial
AJ Gonzalez-Ochoa, JD Raffetto… - Thrombosis and …, 2021 - thieme-connect.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce several
vascular endothelial-dependent systemic complications, and sulodexide has pleiotropic …
vascular endothelial-dependent systemic complications, and sulodexide has pleiotropic …
[HTML][HTML] Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN …
S Charfeddine, H Ibnhadjamor, J Jdidi… - Frontiers in …, 2022 - frontiersin.org
Objective Non-respiratory long-coronavirus disease 2019 (COVID-19) symptoms are mainly
related to a long-lasting endothelial dysfunction and microcirculation impairment. We …
related to a long-lasting endothelial dysfunction and microcirculation impairment. We …
Dapsone and doxycycline could be potential treatment modalities for COVID-19
A Farouk, S Salman - Medical hypotheses, 2020 - ncbi.nlm.nih.gov
The World Health Organization has announced COVID-19 as a pandemic in March 2020.
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome …
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome …
[HTML][HTML] Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study
Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-
19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to …
19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to …
[HTML][HTML] Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
X Liu, Z Li, S Liu, J Sun, Z Chen, M Jiang… - … Pharmaceutica Sinica B, 2020 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute
respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction …
respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction …
[HTML][HTML] Is hydroxychloroquine beneficial for COVID-19 patients?
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar …
syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar …
Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction
X Liu, Z Li, S Liu, Z Chen, J Sun, Z Zhao, Y Huang… - MedRxiv, 2020 - medrxiv.org
The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome
(ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective …
(ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective …
[HTML][HTML] Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study
Dexamethasone provides benefits in patients with coronavirus disease 2019 (COVID-19),
although data regarding immunological profiles and viral clearance are limited. This study …
although data regarding immunological profiles and viral clearance are limited. This study …
[HTML][HTML] Therapeutic potential of resveratrol in COVID-19-associated hemostatic disorders
Coagulation disorders, endotheliopathy and inflammation are the most common hallmarks
in SARS-CoV-2 infection, largely determining COVID-19's outcome and severity …
in SARS-CoV-2 infection, largely determining COVID-19's outcome and severity …
Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS …
MGS Borba, FFA Val, VS Sampaio… - JAMA network …, 2020 - jamanetwork.com
Importance There is no specific antiviral therapy recommended for coronavirus disease
2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate …
2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate …